Finally, other strategies, including CD47 targeting [72,73], CD55/CD59 inhibitors [52,83], the enhancement of NK effector functions via ex vivo expanded NK cells [57,67], and the use of bi-specific molecules [57,84], are under investigation and may represent new therapeutic strategies to improve the outcome of Dara-treated MM patients. Here, CD59 is linked to Miyoshi myopathy.